President, International Gotlib Phyllis sold $3,141 worth of shares (299 units at $10.51), decreasing direct ownership by 0.27% to 108,611 units (SEC Form 4)

$AMWL
Business Services
Consumer Discretionary
Get the next $AMWL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gotlib Phyllis

(Last) (First) (Middle)
C/O AMERICAN WELL CORPORATION
75 STATE STREET, 26TH FLOOR

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
American Well Corp [ AMWL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, International
3. Date of Earliest Transaction (Month/Day/Year)
02/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 02/03/2025 S(1) 299 D $10.5063 108,611 D
Class A Common 64,250 I By Husband
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were made in order to pay the tax liability arising from the vesting and settlement of restricted stock units on February 3, 2025. The sales were effected through and automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person.
/s/ Bradford Gay as attorney-in-fact for Phyllis Gotlib 02/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $AMWL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMWL

DatePrice TargetRatingAnalyst
1/13/2025$15.00Equal Weight → Overweight
Wells Fargo
8/3/2023$5.00 → $2.50Overweight → Equal-Weight
Morgan Stanley
3/23/2023$5.00 → $2.50Outperform → Market Perform
TD Cowen
2/27/2023$5.00 → $3.50Overweight → Neutral
Piper Sandler
1/4/2023$4.20Neutral → Buy
BofA Securities
9/7/2022$5.00Hold
Truist
4/14/2022$6.00Buy
Guggenheim
4/1/2022$5.00Neutral
Credit Suisse
More analyst ratings

$AMWL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Amwell makes inducement grant

    BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units ("RSUs") covering 220,844 shares of its Class A common stock to Dan Zamansky. The grant was offered as material inducement to Zamansky's employment as Amwell's chief product and technology officer. The RSUs become vested as follows, subject to Zamansky's continued employment through each vesting date, except as noted below: 25% of the RSUs will vest on the six-month anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro-rata increments every three (3) m

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell announces innovation leader as chief product and technology officer

    BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, announced Dan Zamansky, an industry leader in innovation and technology, as the company's new chief product and technology officer, effective today. Zamansky will lead the company's product and R&D organizations. He will focus on the comprehensive technology-enabled care platform Amwell offers payers and health systems to provide individuals with better access to more convenient, affordable and effective care. In addition, as more people seek care online and more clinical programs are available, Zamansky will ensure the Amwell platform continues to evolve and provide clients with an integr

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell® makes grants to new employees under inducement plan

    BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on Feb. 18, Amwell made grants of RSUs covering an aggregate of 16,737 shares of its Class A common stock to four new employees. The grants were offered as material inducement to the employees' employment with Amwell. The RSUs will vest as follows, subject to the applicable employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first

    $AMWL
    Business Services
    Consumer Discretionary

$AMWL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AMWL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AMWL
SEC Filings

See more

$AMWL
Leadership Updates

Live Leadership Updates

See more
  • Amwell announces new chief financial officer

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell Announces Appointment of Ricky Goldwasser to its Board of Directors

    Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

    $AMWL
    Business Services
    Consumer Discretionary
  • Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

    ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

    $AMWL
    $AXGN
    Business Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$AMWL
Financials

Live finance-specific insights

See more
  • Amwell® Announces Results for Fourth Quarter and Full Year 2024

    BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell® to report fourth quarter and full year 2024 operating results

    BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Am

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell Announces Results for Third Quarter 2024

    BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will

    $AMWL
    Business Services
    Consumer Discretionary

$AMWL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more